Health Economics›Bladder cancer›Perioperative therapy

Perioperative therapy

Bladder cancer · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cisplatin and Gemcitabine (GC) and Durvalumab Variant #02	—	R 267 040	28d	—	—	8	R 1 346 116 PFS proxy	1

1 of 1 regimen shown